Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Treatment Reports|December 1, 1987
Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancerL Beex, J Burghouts, J van Turnhout, et al.European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex, C Rose, H Mouridsen, et al.Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Endocrine treatment options for advanced breast cancer--the role of fulvestrantJ F R Robertson, S E Come, S E Jones, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.Breast Cancer Research and Treatment|June 9, 2000
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancerA Hamilton, J A Roy, L Beex, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of CancerA Hamilton, L Biganzoli, R Coleman, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 1996
Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group studyE Tomiak, M Piccart, F Mignolet, et al.Journal of the National Cancer Institute|July 19, 2001
Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancerM J Stoutjesdijk, C Boetes, G J Jager, et al.Pageof 2